NASDAQ:EXASEXACT Sciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding EXACT Sciences Co. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $55.75 -1.85 (-3.21 %) (As of 04/5/2020 04:00 PM ET) Add Compare Share Today's Range$54.77Now: $55.75▼$57.6050-Day Range$37.90MA: $70.54▼$102.6452-Week Range$35.25Now: $55.75▼$123.99Volume1.69 million shsAverage Volume3.24 million shsMarket Capitalization$8.25 billionP/E RatioN/ADividend YieldN/ABeta1.76 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.Read More Beat the Market (BTM) Rank™ 4.5 Analyst's Opinion Consensus RatingEXACT Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 16 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $119.43, EXACT Sciences has a potential upside of 114.2% from its current price of $55.75.Amount of Analyst CoverageEXACT Sciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.1 Community Rank Outperform VotesEXACT Sciences has received 865 “outperform” votes. (Add your “outperform” vote.)Underperform VotesEXACT Sciences has received 546 “underperform” votes. (Add your “underperform” vote.)Community SentimentEXACT Sciences has received 61.30% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about EXACT Sciences and other stocks. Vote “Outperform” if you believe EXAS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe EXAS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldEXACT Sciences does not currently pay a dividend.Dividend GrowthEXACT Sciences does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, EXACT Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,462,531.00 in company stock.Percentage Held by InsidersOnly 2.20% of the stock of EXACT Sciences is held by insiders.Percentage Held by Institutions87.77% of the stock of EXACT Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for EXACT Sciences are expected to decrease by -71.05% in the coming year, from ($1.90) to ($0.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of EXACT Sciences is -76.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of EXACT Sciences is -76.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEXACT Sciences has a P/B Ratio of 3.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.72 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Commercial physical research Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:EXAS Previous Symbol CUSIP30063P10 CIK1124140 Webhttp://www.exactsciences.com/ Phone608-284-5700Debt Debt-to-Equity Ratio0.41 Current Ratio2.36 Quick Ratio2.09Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$876.29 million Price / Sales9.41 Cash FlowN/A Price / Cash FlowN/A Book Value$17.62 per share Price / Book3.16Profitability EPS (Most Recent Fiscal Year)($1.49) Net Income$-83,990,000.00 Net Margins-9.59% Return on Equity-18.78% Return on Assets-9.75%Miscellaneous Employees4,110 Outstanding Shares147,970,000Market Cap$8.25 billion Next Earnings Date5/5/2020 (Estimated) OptionableOptionable Receive EXAS News and Ratings via Email Sign-up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:EXAS Rates by TradingView EXACT Sciences (NASDAQ:EXAS) Frequently Asked Questions How has EXACT Sciences' stock been impacted by COVID-19 (Coronavirus)? EXACT Sciences' stock was trading at $57.82 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, EXAS stock has decreased by 3.6% and is now trading at $55.75. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of EXACT Sciences? 16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for EXACT Sciences in the last year. There are currently 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for EXACT Sciences. When is EXACT Sciences' next earnings date? EXACT Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for EXACT Sciences. How were EXACT Sciences' earnings last quarter? EXACT Sciences Co. (NASDAQ:EXAS) released its earnings results on Tuesday, February, 11th. The medical research company reported $0.54 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.37) by $0.91. The medical research company earned $295.58 million during the quarter, compared to analysts' expectations of $294.39 million. EXACT Sciences had a negative net margin of 9.59% and a negative return on equity of 18.78%. View EXACT Sciences' earnings history. What guidance has EXACT Sciences issued on next quarter's earnings? EXACT Sciences issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, February, 11th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.61-1.645 billion, compared to the consensus revenue estimate of $1.59 billion. What price target have analysts set for EXAS? 16 brokers have issued 1-year price targets for EXACT Sciences' stock. Their forecasts range from $70.00 to $143.00. On average, they anticipate EXACT Sciences' share price to reach $119.43 in the next year. This suggests a possible upside of 114.2% from the stock's current price. View analysts' price targets for EXACT Sciences. What are Wall Street analysts saying about EXACT Sciences stock? Here are some recent quotes from research analysts about EXACT Sciences stock: 1. According to Zacks Investment Research, "Over the past year, Exact Science has been outperforming its industry. The company has demonstrated strength across its entire business, driven by impressive performances with its Cologuard business. It is also progressing well in terms of its three priorities in 2019. We are currently looking forward to Exact Science’s recently-closed merger with advanced molecular diagnostics company Genomic Health. The company exhibited an impressive performance with better-than-expected earnings results in the third quarter of 2019. On the flip side, escalating expenses are putting pressure on operating margin. Sole reliance on Cologuard and competitive headwinds persist as major downsides." (1/21/2020) 2. Canaccord Genuity analysts commented, "We are buyers of EXAS following the unusual 10% weakness in shares today, which we believe were part of the overall selloff today in diagnostics (and software stocks), where much of the alpha in the overall stock market has come from; and what we believe is likely certain funds pressuring EXAS following a cost effectiveness study published last week, but got a lot more attention today on the Street. We believe this is a buy-on- weakness opportunity on shares of EXAS given a handful of deep flaws used in the study." (9/10/2019) Has EXACT Sciences been receiving favorable news coverage? News headlines about EXAS stock have trended very negative on Sunday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. EXACT Sciences earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave headlines about the medical research company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutEXACT Sciences. Who are some of EXACT Sciences' key competitors? Some companies that are related to EXACT Sciences include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN). What other stocks do shareholders of EXACT Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other EXACT Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Aduro BioTech (ADRO), salesforce.com (CRM), Paypal (PYPL), Advanced Micro Devices (AMD), Square (SQ) and AT&T (T). Who are EXACT Sciences' key executives? EXACT Sciences' management team includes the following people: Mr. Kevin T. Conroy, Chairman, Pres & CEO (Age 53)Mr. Jeffrey T. Elliott CFA, Chief Financial Officer (Age 41)Mr. Graham P. Lidgard, Chief Science Officer (Age 70)Mr. D. Scott Coward, Chief Admin. Officer, Sr. VP, Gen. Counsel & Sec. (Age 54)Mr. Mark Stenhouse, Pres of Cologuard (Age 52) What is EXACT Sciences' stock symbol? EXACT Sciences trades on the NASDAQ under the ticker symbol "EXAS." How do I buy shares of EXACT Sciences? Shares of EXAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is EXACT Sciences' stock price today? One share of EXAS stock can currently be purchased for approximately $55.75. How big of a company is EXACT Sciences? EXACT Sciences has a market capitalization of $8.25 billion and generates $876.29 million in revenue each year. The medical research company earns $-83,990,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis. EXACT Sciences employs 4,110 workers across the globe. View additional information about EXACT Sciences. What is EXACT Sciences' official website? The official website for EXACT Sciences is http://www.exactsciences.com/. How can I contact EXACT Sciences? EXACT Sciences' mailing address is 441 CHARMANY DRIVE, MADISON WI, 53719. The medical research company can be reached via phone at 608-284-5700. This page was last updated on 4/5/2020 by MarketBeat.com StaffFeatured Article: What are the disadvantages of after-hours trading?
